ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,495.10
0.14%
S&P ASX All Technology
4,034.80
1.05%
Brent Oil
75.785
-0.18%
US Dollar vs AUD
1.59418
-0.04%
Bitcoin
98,070.17
0.60%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Johnson & Johnson (0R34)

  7. Johnson & Johnson (0R34) News

0R34

Johnson & Johnson (0R34)

Johnson & Johnson
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0R34
DateTimeSourceHeadlineSymbolCompany
03/02/202521:44Alliance NewsAlliance NewsJ&J secures CHMP backing for subcutaneous Rybrevant in lung cancerLSE:0R34Johnson & Johnson
22/01/202523:03Alliance NewsAlliance NewsJohnson & Johnson reports sales growth following "transformative year"LSE:0R34Johnson & Johnson
13/01/202523:36Alliance NewsAlliance NewsJ&J acquires schizophrenia drug in USD14.6 billion Intra-Cellular dealLSE:0R34Johnson & Johnson
21/11/202401:13Alliance NewsAlliance NewsJohnson & Johnson risks UK lawsuit over talc cancer claimLSE:0R34Johnson & Johnson
15/10/202422:36Alliance NewsAlliance NewsTOP NEWS: Johnson & Johnson ups sales outlook but cuts profit guideLSE:0R34Johnson & Johnson
10/10/202405:36Alliance NewsAlliance NewsTOP NEWS: J&J USD600 million V-Wave purchase to cut earnings per shareLSE:0R34Johnson & Johnson
20/08/202422:12Alliance NewsAlliance NewsJ&J to pay up to USD1.7 billion for heart failure device firm V-WaveLSE:0R34Johnson & Johnson
17/07/202421:25Alliance NewsAlliance NewsTOP NEWS: Johnson & Johnson touts "robust pipeline" as sales riseLSE:0R34Johnson & Johnson
31/05/202423:30Alliance NewsAlliance NewsJohnson & Johnson ties up acquisition of Shockwave MedicalLSE:0R34Johnson & Johnson
01/05/202423:17Alliance NewsAlliance NewsTOP NEWS: J&J proposes USD6.48 billion settlement of cancer lawsuitsLSE:0R34Johnson & Johnson
16/04/202420:54Alliance NewsAlliance NewsTOP NEWS: Johnson & Johnson upgrades guidance on swing to earningsLSE:0R34Johnson & Johnson
05/04/202422:02Alliance NewsAlliance NewsTOP NEWS: J&J swoops for Shockwave Medical in USD13.1 billion dealLSE:0R34Johnson & Johnson
26/03/202405:28Alliance NewsAlliance NewsIN BRIEF: J&J submits US premarket approval application for VaripulseLSE:0R34Johnson & Johnson
18/03/202422:10Alliance NewsAlliance NewsIN BRIEF: Johnson & Johnson receives FDA recommendation for CarvyktiLSE:0R34Johnson & Johnson
24/02/202405:32Alliance NewsAlliance NewsIN BRIEF: Johnson & Johnson gets EMA nod for Carvykti in myelomaLSE:0R34Johnson & Johnson
02/02/202417:22Alliance NewsAlliance NewsTOP NEWS: US sends drugmakers initial offers in Medicare price talksLSE:0R34Johnson & Johnson
23/01/202422:41Alliance NewsAlliance NewsTOP NEWS: Johnson & Johnson eyes future growth; 2023 sales riseLSE:0R34Johnson & Johnson
20/01/202408:34Alliance NewsAlliance NewsIN BRIEF: J&J gets US FDA approval for cancer treatment BalversaLSE:0R34Johnson & Johnson
06/12/202300:24Alliance NewsAlliance NewsTOP NEWS: J&J expects strong long-term growth in three key driversLSE:0R34Johnson & Johnson
23/10/202322:03Alliance NewsAlliance NewsJ&J report slew of positive trial results focused on various cancersLSE:0R34Johnson & Johnson
17/10/202321:46Alliance NewsAlliance NewsTOP NEWS: J&J raises full-year sales outlook after "solid" quarterLSE:0R34Johnson & Johnson
07/10/202302:52Alliance NewsAlliance NewsIN BRIEF: J&J applies for indication extension to EMA for RybrevantLSE:0R34Johnson & Johnson
04/10/202303:00Alliance NewsAlliance NewsDrugmakers agree to US government price talks amid pushbackLSE:0R34Johnson & Johnson
07/09/202315:50Alliance NewsAlliance NewsJ&J's Janssen ends Phase 3 MACiTEPH study evaluating macitentanLSE:0R34Johnson & Johnson
31/08/202302:07Alliance NewsAlliance NewsTOP NEWS: J&J forecasts strong growth in earnings after Kenvue splitLSE:0R34Johnson & Johnson
11/08/202306:34Alliance NewsAlliance NewsIN BRIEF: Johnson & Johnson's blood cancer therapy approved by FDALSE:0R34Johnson & Johnson
20/07/202321:30Alliance NewsAlliance NewsTOP NEWS: J&J ups full-year guidance after "robust" second quarterLSE:0R34Johnson & Johnson
31/05/202301:48Alliance NewsAlliance NewsJ&J seeks FDA approval for pulmonary arterial hypertension treatmentLSE:0R34Johnson & Johnson
10/05/202305:23Alliance NewsAlliance NewsJ&J says Tremfya data shows positive results for ulcerative colitisLSE:0R34Johnson & Johnson
04/05/202321:41Alliance NewsAlliance NewsIN BRIEF: J&J prices subsidiary Kenvue's NYSE initial public offeringLSE:0R34Johnson & Johnson
 Showing the most relevant articles for your search:LSE:0R34

Your Recent History

NYSE
MCD
McDonalds
ASX
QBE
QBE Insurance
NASDAQ
GOOGL
Alphabet
NASDAQ
NVDA
NVIDIA
NASDAQ
MSFT
Microsoft
FX
AUDJPY
AUD vs Yen
COIN
DOGEUSD
Dogecoin
NYSE
XOM
Exxon Mobil
ASX
XJO
S&P ASX 200
ASX
RIO
Rio Tinto
NYSE
VZ
Verizon Communications
ASX
WES
Wesfarmers
ASX
ANZ
Australia And New Zealan...
ASX
SUN
Suncorp
ASX
WPL
Woodside Petroleum
NASDAQ
QQQ
Invesco QQQ Trust Series 1
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads